Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
[ABSTRAK
Gastro Entero Pancreatic Neuro Endocrine Tumor (GEP-NET) merupakan keganasan yang jarang dijumpai di dunia dibandingkan dengan keganasan gastrointestinal lainnya. Menurut data GEP-NET kadang sulit dibedakan dengan Irritabel Bowel Syndrome (IBS) dalam mendiagnosisnya. Keluhan GEP-NET antara lain nyeri perut, diare, flushing, sampai penurunan berat badan. Keluhan IBS antara lain nyeri perut, mual, diare atau dengan tanpa konstipasi. Saat ini telah dikembangkan pemeriksaan Chromogranin A (CgA) untuk membantu dalam pemeriksaan penapisan pasien yang menderita IBS maupun pasien yang dicurigai GEP-NET. Penelitian ini merupakan penelitian deskriptif untuk mengetahui kadar CgA pada kelompok normal, mengetahui kadar CgA pada pasien yang didiagnosis IBS, mengetahui kadar CgA pada pasien yang memiliki risiko GEP-NET dan mengetahui perbedaan kadar CgA pada pasien yang didiagnosis IBS dan pasien yang dicurigai menderita GEP-NET yang keduanya memiliki risiko GEP-NET. Pada penelitian ini didapatkan kadar CgA serum pada kelompok kontrol normal dengan nilai mean 50,70 μg/L, median 48,89 μg/L dengan rentang minimum-maksimum antara 42,66-80,62 μg/L. Pada penelitian ini didapatkan kadar CgA serum pada kelompok IBS dengan nilai mean 76,67 μg/L, median 64,82 μg/L dengan rentang minimum-maksimum antara 45,52-243,18 μg/L. Pada penelitian ini didapatkan kadar CgA serum pada kelompok yang dicurigai GEP- NET denga nilai mean median 66,23 μg/L dengan rentang minimum-maksimum antara 49,89-656,41 μg/L.Pada penelitian ini tidak terdapat perbedaan kadar CgA pada populasi pasien yang didiagnosa IBS maupun pada pasien yang dicurigai menderita GEP-NET yang keduanya memiliki risiko menderita GEP-NET dikemudian hari.

---

ABSTRACT
Gastro Entero Pancreatic Neuro Endocrine Tumors (GEP-NET) is a malignancy that is rarely found in the world compared to other gastrointestinal malignancies. According to data registration data The Surveillance, Epidemiology and End Results (SEER) an increase in the incidence of sharp from 1973 (from 0.92 to 1.28 in 100,000 population per year), to 2004 (from 5.09 to 5.42 in 100,000 population per year). GEP-NET is difficult to distinguish from Irritabel Bowel Syndrome (IBS) in diagnose sometimes. GEP-NET complaints include abdominal pain, diarrhea, flushing, until the weight loss. Complaints of IBS include abdominal pain, nausea, diarrhea or with no constipation. We have been developed examination Chromogranin A (CgA) to assist in the screening examination of patients who suffer from IBS and patients who are suspected of suffering from GEP-NET.This study is a descriptive study to determine levels of CgA in the normal group, knowing CgA levels in patients diagnosed IBS, knowing CgA levels in patients who have a risk of GEP-NET and know the difference CgA levels in patients diagnosed with IBS and patients suspected of suffering from GEP- NET who both have risk GEP-NET. In this study, serum levels of CgA in the normal control group with a mean of 50,70 μg/L, median 48,89 μg / L with a minimum-maximum range between 42,66 to 80,62 μg/L. In this study, serum levels of CgA in the IBS group with a mean of 76,67μg /L, median 64,82 μg/L with a minimum-maximum range between 45,52 to 243,18 μg/L. In this study, serum levels of CgA in the group suspected of GEP-NET premises mean median value 66,23 μg/L with a minimum-maximum range between 49.89 to 656.41 g / L. In this study there was no difference in the levels of CgA IBS patients diagnosed population and in patients suspected of suffering from GEP-NET are both at risk of suffering from GEP-NET in the future., Gastro Entero Pancreatic Neuro Endocrine Tumors (GEP-NET) is a malignancy that is rarely found in the world compared to other gastrointestinal malignancies. According to data registration data The Surveillance, Epidemiology and End Results (SEER) an increase in the incidence of sharp from 1973 (from 0.92 to 1.28 in 100,000 population per year), to 2004 (from 5.09 to 5.42 in 100,000 population per year). GEP-NET is difficult to distinguish from Irritabel Bowel Syndrome (IBS) in diagnose sometimes. GEP-NET complaints include abdominal pain, diarrhea, flushing, until the weight loss. Complaints of IBS include abdominal pain, nausea, diarrhea or with no constipation. We have been developed examination Chromogranin A (CgA) to assist in the screening examination of patients who suffer from IBS and patients who are suspected of suffering from GEP-NET.This study is a descriptive study to determine levels of CgA in the normal group, knowing CgA levels in patients diagnosed IBS, knowing CgA levels in patients who have a risk of GEP-NET and know the difference CgA levels in patients diagnosed with IBS and patients suspected of suffering from GEP- NET who both have risk GEP-NET. In this study, serum levels of CgA in the normal control group with a mean of 50,70 μg/L, median 48,89 μg / L with a minimum-maximum range between 42,66 to 80,62 μg/L. In this study, serum levels of CgA in the IBS group with a mean of 76,67μg /L, median 64,82 μg/L with a minimum-maximum range between 45,52 to 243,18 μg/L. In this study, serum levels of CgA in the group suspected of GEP-NET premises mean median value 66,23 μg/L with a minimum-maximum range between 49.89 to 656.41 g / L. In this study there was no difference in the levels of CgA IBS patients diagnosed population and in patients suspected of suffering from GEP-NET are both at risk of suffering from GEP-NET in the future.]

Abstrak :
ABSTRAK
Latar belakang : Insiden Adenokarsinoma di RSCM meningkat pada periode 2001-2006 dibanding periode sebelumnya 1995-2000 . Banyak penderita yang resisten terhadap pengobaan hormonal. Resistensi ini diduga akibat sel tumor mengalami transformasi Neuroendokrin. Akan dilakukan penelitian untuk melihat ekspresi Androgen Receptor AR dan Chromogranin A CgA pada adenokarsinoma prostat di RSCM tahun 2011-2015.Tujuan : Membuktikan korelasi ekspresi AR dan CgA dengan derajat keganasan.Metode : Studi potong lintang analitik terhadap 70 kasus adenokarsinoma prostat di departemen PA FKUI/RSCM tahun 2011-2015. Kasus dipulas imunohistokimia AR dan Cg A serta dilakukan interpretasi hasil. AR dinilai prosentase positivitasnya pada inti epitel dan stromal. CgA dinilai prosentase positivitasnya pada sitoplasma. Uji korelasi dilakukan untuk melihat kemaknaan dan kekuatan korelasi antar variabel terikat.Hasil : Karakteristik sampel usia 47,1 >70 tahun; diferensiasi histopatologik/skor gleason 42,9 buruk/>7, grade group 28,6 grade5 dan PSA 64,3 dalam rentang 11-100ng/ml. Ekspresi CgA berkorelasi negatif lemah dengan ekspresi AR epitel r=-0,288;p=0,016 . Ekspresi CgA tidak berkorelasi dengan ekspresi AR stromal p=0,886 . Terdapat hubungan bermakna ekspresi AR epitel dengan grade group p=0,003 . Tidak terdapat hubungan bermakna ekspresi AR epitel dengan usia, diferensiasi histopatologik/skor gleason dan PSA. Ekspresi CgA berhubungan bermakna dengan diferensiasi histopatologik/skor gleason dan grade group p=0,018;p=0,038 . Tidak terdapat hubungan bermakna ekspresi CgA dengan usia dan PSA. Ekspresi AR stromal tidak berhubungan bermakna dengan usia, diferensiasi histopatologik, grade group, skor gleason, maupun PSA.Kesimpulan : Terdapat korelasi yang lemah antara AR dan CgA sehingga pulasan AR dan CgA dapat dipakai untuk pemilihan terapi.

---

ABSTRACT
Background Prevalence of prostate adenocarcinoma doubled in 2001 2006 compared to 1995 2000 in RSCM. Many patients resistant to hormonal treatment. This resistance is thought to be due to tumor cells undergoing neuroendocrine transformation. Study will be conducted to analyze the expression of Androgen Receptor AR and Chromogranin A CgA in prostate adenocarcinoma at RSCM in 2011 2015. Objective To prove correlation of expression of AR and CgA with degree of malignancy. Methods A cross sectional study was carried out on 70 cases of prostate adenocarcinoma in department of Anatomic Pathology FKUI RSCM from 2011 2015. AR expressed in stromal and epithelial nuclei, CgA expressed in cytoplasm. Statistical tests used to discover significance and correlation between the dependent variables. Results Most samples are more than 70 years old 47,1 , has poor histologic gleason score 42.9 , are in clinical grade 5 28.6 , and has PSA score range between 11 100 ng ml. CgA expression negatively correlates to epithelial AR expression r 0,288 p 0.016 , while no correlation are found between CgA expression and stromal AR expression p 0.886 . There is significant difference between epithelial AR expression with grade group p 0.003 , but not with age, histopathologic differentiation Gleason score and PSA. There are significant difference between CgA expression and histopathologic differentiation grade group and Gleason score p 0.018 p 0.038 , but not with age and PSA. No significant difference observed between stromal AR expression with age, histopathologic differentiation gleason score, grade group or PSA. Conclusion There rsquo s a weak correlation between AR and CgA so that AR and CgA expression can be used for the selection of therapy.